In the News

AVflo™ presented at the Central Venous Pathology Summit in Kennesaw, GA, USA

April 18, 2013

 

CryoLife Inc., a leading tissue processing and medical device company focused on cardiac and vascular surgery, hosted a Central Venous Pathology (CVP) Summit at CryoLife's corporate headquarters in suburban Atlanta and at the St. Joseph Translational Research Institute in Atlanta, Georgia.

 

The CVP summit examined treatment strategies for durable hemodialysis access in cases of central venous pathology through an interactive, data-driven and clinically-focused didactic and hands-on wet lab practicum.

 

CryoLife presented the HeRO® Graft and invited several private companies with emerging technology related to central venous stenosis and durable hemodialysis access to present at the Summit. Approximately 75 physicians and dialysis therapy professionals attended the two-day event. Nicast presented its AVflo™ vascular access graft and demonstrated its advantages.

Do not say "Fistula first" say "CVC last". This was the main message from the CVP Summit. In presentation summarizing evidence from the US Renal Data System (http://www.usrds.org/qtr/default.aspx), it was declared that about 80% of all the dialysis patients begin with a “Neck Catheter” instead of having a permanent access. Around 60% of these patients do not have any other alternatives such as fistula or graft planned.

 

The complications of CVC include thrombosis and infections, who could be life threatening in the anatomical surroundings of the catheter. In view of the long maturation times of ePTFE Grafts and native fistulas, it makes more sense to use early access, long term solutions like the HeRO™ graft by patients without any usable veins in the arms or AVflo™, when adequate vessels are available but a rapid access is beneficial.


 

back
Mike Wallace Jersey Mike Tolbert Jersey Kyle Long Jersey Sean Lee Jersey Shane Ray Jersey Ameer Abdullah Jersey Jared Cook Jersey Nick Novak Jersey